Compare AbCellera Biologics Inc (ABCL) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Utilities Select Sector SPDR Fund — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Utilities Select Sector SPDR Fund trades at $45.4. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABCL | XLU | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $47.73 |
52-Week Low | $2.78 | $40.57 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
XLU trades at $45.30, down 1.01% today, with a bullish technical signal supported by moving averages. The ETF provides pure exposure to US utilities, benefiting from AI-driven power demand growth. Recent news highlights utilities' role in powering AI data centers, with top holdings securing long-term clean energy agreements. Technical indicators show neutral oscillators but bullish ADX signals, with key support at $44-$45 and resistance at $46.
The outlook for XLU is positive due to structural demand growth from AI infrastructure, though valuation metrics are unavailable. Risks include interest rate sensitivity and regulatory uncertainty. Analyst sentiment is mixed, with utilities transitioning from bond proxies to growth plays amid rising power needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
